Mektovi is a medicine used in adults for treating certain cancers when their cells have a mutation (change) in their genes called 'BRAF V600'. Mektovi is used in combination with another medicine, encorafenib , to treat: - melanoma (a skin cancer) that has spread or cannot be removed by surgery; - a type of lung cancer called non-small cell lung cancer (NSCLC). It is used when the cancer is advanced and has the BRAF V600E version of the mutation. Mektovi contains the active substance binimetinib.
Therapeutic Indication
### Therapeutic indication Melanoma Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Non-small cell lung cancer (NSCLC) Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
Therapeutic Area (MeSH)
N/AATC Code
L01EE03
ATC Item
binimetinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| binimetinib | N/A | Binimetinib |
EMA Name
Mektovi
Medicine Name
Mektovi
Aliases
N/ANo risk management plan link.
